Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda
Top Cited Papers
- 1 August 2002
- journal article
- review article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 2 (8) , 494-501
- https://doi.org/10.1016/s1473-3099(02)00347-x
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Drug development for neglected diseases: a deficient market and a public-health policy failureThe Lancet, 2002
- Developments in the treatment of leishmaniasis and trypanosomiasisEmerging Drugs, 2002
- Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial Commentary: cost and resistance remain issuesBMJ, 2001
- Influence of Highly Active Antiretroviral Therapy on the Outcome of Subclinical Visceral Leishmaniasis in Human Immunodeficiency Virus-Infected PatientsClinical Infectious Diseases, 2001
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- Multi‐centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasisTropical Medicine & International Health, 1999
- The Reemergence of Visceral Leishmaniasis in BrazilEmerging Infectious Diseases, 1996
- Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United KingdomTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, IndiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Malnutrition as a Risk Factor for Severe Visceral LeishmaniasisThe Journal of Infectious Diseases, 1987